Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 7:52 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 457–480 of 3,094 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: M.D. Anderson Cancer Center Clear all
Terminated Phase 2 Interventional

Malignant Mixed Mesodermal Tumor (MMMT) - Early Stage With Postoperative XRT/Chemotherapy

NCT00505492
View directory record Official record
Conditions
Uterine Neoplasms
Interventions
Carboplatin, Cisplatin, Paclitaxel
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
2
States / cities
Houston, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 15, 2011 · Synced Oct 14, 2026, 7:52 AM EDT
Recruiting Phase 3 Interventional

Trial Of PreoperAtive Radiation (TOPAz): A Randomized Trial Comparing Hypofractionated Versus Conventionally Fractionated Preoperative Radiation Followed by Mastectomy With Immediate Autologous Breast Reconstruction With Integrated Tissue Nanomechanical Phenotype Evaluation

NCT05774678
View directory record Official record
Conditions
Breast Cancer
Interventions
Group 1 (preoperative radiation hypofractionated), Group 2 (preoperative radiation conventionally fractionated)
Radiation · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 14, 2026, 7:52 AM EDT
Recruiting Phase 2 Interventional

A Phase 2 Platform Study of Immunomodulatory Compounds in ICI-refractory Non-small Cell Lung Cancer

NCT07133425
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, ICI-refractory
Interventions
SAR445877
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2026 · Synced Oct 14, 2026, 7:52 AM EDT
Terminated Phase 3 Interventional Results available

Spectroscopy Versus Standard Care in Cervical Cancer Patients

NCT00529464
View directory record Official record
Conditions
Cervical Cancer
Interventions
Fluorescence Spectroscopy, Colposcopy, LEEP Procedure
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 9, 2016 · Synced Oct 14, 2026, 7:52 AM EDT
Terminated Phase 1 Interventional

A First-in-Man, Phase I Evaluation of A Single Cycle of Prohibitin Targeting Peptide 1 in Patients With Metastatic Prostate Cancer and Obesity

NCT01262664
View directory record Official record
Conditions
Prostate Cancer
Interventions
Prohibitin-TP01
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 4, 2019 · Synced Oct 14, 2026, 7:52 AM EDT
Recruiting Phase 2 Interventional

Laser Interstitial Thermal Therapy (LITT) or Surgery and Adjuvant Reirradiation for Recurrent Brain Metastases (LaSAR BeaM)

NCT07053033
View directory record Official record
Conditions
Brain Metastases
Interventions
Surgery, LITT
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 14, 2026, 7:52 AM EDT
Completed Phase 2 Interventional

Best Systemic Therapy or Best Systemic Therapy (BST) Plus Definitive Treatment (Radiation or Surgery)

NCT01751438
View directory record Official record
Conditions
Prostate Cancer
Interventions
Best Systemic Therapy (BST), Best Systemic Therapy (BST) + Surgery or Radiation Therapy, Questionnaires, Phone Call/Email
Other · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
3
States / cities
San Francisco, California • Philadelphia, Pennsylvania • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Oct 14, 2026, 7:52 AM EDT
Completed Phase 2 Interventional

Amifostine in Treating Patients With Myelodysplastic Syndrome

NCT00003048
View directory record Official record
Conditions
Myelodysplastic Syndromes
Interventions
Amifostine Trihydrate
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 25, 2018 · Synced Oct 14, 2026, 7:52 AM EDT
Completed Phase 2 Interventional Results available

Ramucirumab in Treating Patients With Advanced or Metastatic, Previously Treated Biliary Cancers That Cannot Be Removed by Surgery

NCT02520141
View directory record Official record
Conditions
Cholangiocarcinoma, Liver and Intrahepatic Bile Duct Carcinoma, Stage III Gallbladder Cancer AJCC v7, Stage III Intrahepatic Cholangiocarcinoma AJCC v7, Stage IIIA Gallbladder Cancer AJCC v7, Stage IIIB Gallbladder Cancer AJCC v7, Stage IV Gallbladder Cancer AJCC v7, Stage IVA Gallbladder Cancer AJCC v7, Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7, Stage IVB Gallbladder Cancer AJCC v7, Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7, Unresectable Gallbladder Carcinoma
Interventions
Laboratory Biomarker Analysis, Ramucirumab
Other · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 15, 2023 · Synced Oct 14, 2026, 7:52 AM EDT
Recruiting Not applicable Interventional

Identifying Underserved Individuals inTexas With Hereditary Cancer Risk Using Mobile Mammography Units and Telegenetics.

NCT05649072
View directory record Official record
Conditions
Ovarian Cancer, Breast Cancer, Colorectal Cancer
Interventions
Genetic Testing and Counseling, Screening Form
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 22, 2026 · Synced Oct 14, 2026, 7:52 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Endothelial Dysfunction As A Predictor Of Perioperative Outcome

NCT00384683
View directory record Official record
Conditions
Endothelial Dysfunction
Interventions
Not listed
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2019 · Synced Oct 14, 2026, 7:52 AM EDT
Recruiting Phase 2 Interventional

Phase II Study Of Nivolumab Plus AVD In Pediatric, Adolescent, And Young Adult Patients With CHL

NCT07551583
View directory record Official record
Conditions
Hodgkin Lymphoma
Interventions
Nivolumab, Doxorubicin Hydrochloride, Vinblastine, Dacarbazine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
2 Years to 21 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 14, 2026, 7:52 AM EDT
Completed Phase 1 Interventional

Study of Cytoreductive Surgery and Hyperthermic Intrathoracic Pleural Chemotherapy (HITC) With Escalating Doses for Children and Adolescents With Unilateral Pleural Malignancy

NCT01998529
View directory record Official record
Conditions
Lung Cancer
Interventions
Cisplatin, Amifostine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
3 Years to 21 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 14, 2023 · Synced Oct 14, 2026, 7:52 AM EDT
Completed Phase 2 Interventional

Delayed-Immediate Breast Reconstruction

NCT00473122
View directory record Official record
Conditions
Breast Cancer
Interventions
Delayed-Immediate Breast Reconstruction
Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2015
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2016 · Synced Oct 14, 2026, 7:52 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Lifestyle Intervention for the Reduction of Prostate Cancer Disparities Among African Americans

NCT04215029
View directory record Official record
Conditions
Cancer Survivor, Partner, Spouse, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8
Interventions
Exercise Intervention, Informational Intervention, Interview, Nutritional Assessment, Questionnaire Administration, Telephone-Based Intervention
Behavioral · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 14, 2026, 7:52 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Assessment of Sexual Dysfunction, Depression and Anxiety in Underserved, Minority Gynecologic Cancers Patients

NCT01031602
View directory record Official record
Conditions
Gynecologic Cancer
Interventions
Surveys
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 29, 2013 · Synced Oct 14, 2026, 7:52 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

3rd Party LMP1/2-Specific Cytotoxic T Lymphocytes for EBV-Associated Lymphoma

NCT02057445
View directory record Official record
Conditions
Non-Hodgkins Lymphoma, Hodgkins Lymphoma, Lymphoproliferative Disorder
Interventions
EBV CTL's, Peripheral Blood Donor
Drug · Other
Lead sponsor
New York Medical College
Other
Eligibility
1 Year and older
Enrollment
1 participant
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2017
U.S. locations
2
States / cities
Washington D.C., District of Columbia • Valhalla, New York
Source: ClinicalTrials.gov public record
Updated Dec 22, 2017 · Synced Oct 14, 2026, 7:52 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer

NCT00317772
View directory record Official record
Conditions
Ovarian Cancer, Peritoneal Neoplasms, Fallopian Tube Cancer
Interventions
Topotecan, Gefitinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 7, 2022 · Synced Oct 14, 2026, 7:52 AM EDT
Recruiting No phase listed Observational

Universal Biospecimen Collection Protocol for Extra Material From Clinical Pulmonary Procedures

NCT07218939
View directory record Official record
Conditions
Pulmonary
Interventions
Not listed
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Oct 14, 2026, 7:52 AM EDT
Completed Phase 2 Interventional Results available

Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer

NCT03279250
View directory record Official record
Conditions
Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8
Interventions
Abiraterone Acetate, Apalutamide, Gonadotropin-releasing Hormone Analog, Prednisone, Radical Prostatectomy
Drug · Biological · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Male only
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2022 · Synced Oct 14, 2026, 7:52 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma

NCT01833520
View directory record Official record
Conditions
Sarcoma
Interventions
Ra-223 Dichloride
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
15 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Oct 14, 2026, 7:52 AM EDT
Completed Phase 3 Interventional Results available

Extraperitoneal Para-aortic Lymph Node Dissection (EPLND) for Cervix

NCT01365156
View directory record Official record
Conditions
Cervical Squamous Cell Carcinoma, Adenosquamous Carcinoma, Adenocarcinoma, Locally Advanced Malignant Neoplasm, Cervical Cancer
Interventions
Extraperitoneal laparoscopic lymphadenectomy (EPLND), Chemoradiation
Procedure · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2020
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 3, 2021 · Synced Oct 14, 2026, 7:52 AM EDT
Recruiting Phase 1Phase 2 Interventional

Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab

NCT06287229
View directory record Official record
Conditions
Relapsed/Refractory, B-cell Acute Lymphocytic Leukemia
Interventions
Blinatumomab, Inotuzumab Ozogamicin, Hyper-CVAD, Mini-hyper-CVD
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 14, 2026, 7:52 AM EDT
Terminated Phase 2 Interventional Results available

Obatoclax for Systemic Mastocytosis

NCT00918931
View directory record Official record
Conditions
Leukemia, Systemic Mastocytosis
Interventions
Obatoclax Mesylate
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 4, 2011 · Synced Oct 14, 2026, 7:52 AM EDT